Search

Researchers from MSK presented promising studies on treating rare solid tumors including mesothelioma and three types of soft-tissue at the annual meeting of the American Society of Clinical Oncology.

… Monday, June 3, 2024 Researchers from Memorial Sloan Kettering Cancer Center (MSK) presented several promising studies on treating rare solid tumors at the annual meeting of the American Society of Clinical Oncology (ASCO). The results of clinical trials focused on mesothelioma and three types of soft-tissue

Learn how a new treatment approach using high-dose radiation has given hope to people with inoperable tumors.

… Tuesday, October 2, 2018 Summary People with  liver cancer  or  pancreatic cancer sometimes have tumors that are too large to be removed through surgery. Conventional radiation doses are not able to control these tumors. A new radiation approach using higher doses can sometimes control large tumors in

Meet Dario Cortes, who was treated for rectal cancer at Memorial Sloan Kettering and is now back to doing the activities he loves.

… Tuesday, December 18, 2018 VIDEO | 01:02 The stages of colon cancer Video Details Summary Dario Cortes was diagnosed with rectal cancer in 2015. He started chemotherapy and radiation at Memorial Sloan Kettering and had no evidence of disease when he finished treatment. When the cancer returned six months

Conozca a Dario Cortes, que recibió tratamiento para el cáncer rectal en el Memorial Sloan Kettering y ahora hace las actividades que ama.

… Tuesday, December 18, 2018 VIDEO | 01:02 The stages of colon cancer Video Details Resumen Dario Cortes recibió el diagnóstico de cáncer rectal en 2015. Comenzó quimioterapia y radiación en Memorial Sloan Kettering y no mostraba evidencia de enfermedad cuando terminó el tratamiento. Cuando el cáncer regresó

Memorial Sloan Kettering has announced the creation of the Louis V. Gerstner, Jr. Young Investigators Fund and has named the fund's first four recipients.

… Friday, May 1, 2009 Summary Memorial Sloan Kettering has announced the creation of the Louis V. Gerstner, Jr. Young Investigators Fund and has named the fund’s first four recipients. Memorial Sloan Kettering has announced the creation of the Louis V. Gerstner, Jr. Young Investigators Fund and has named

Researchers found that a common cancer gene called PIK3CA also causes the condition venous malformation. Their discovery has already pointed the way to targeted therapies for this rare and painful condition that affects one in 10,000 people.

… Wednesday, March 30, 2016 Summary MSK researchers have made a surprising finding: A common cancer gene called PIK3CA also causes the condition venous malformation. Their discovery has already pointed the way to targeted therapies for this rare and painful condition that affects one in 10,000 people.

Meet MSK Research Scholar Moralba Dominguez Garcia, PhD: “I wanted to do something that creates knowledge — and that can help other people.”

… Friday, June 6, 2025 For Moralba (Mora) Dominguez Garcia, PhD , being a Research Scholar developing radiopharmaceuticals against cancer is a dream come true.  Like so many trainees who come to Memorial Sloan Kettering Cancer Center (MSK) from around the world after earning a PhD, she was drawn by the

Learn how HPV-related head and neck cancer can be treated with a sharply reduced radiation dose to prevent side effects, sometimes without surgery.

… Friday, September 20, 2024 An innovative radiation treatment approach that is typically given to patients after surgical removal of HPV-positive head and neck tumors may now help some of those patients avoid surgery altogether.  The approach, pioneered by Memorial Sloan Kettering Cancer Center (MSK)

A new analysis of survival data for the randomized, phase III PACIFIC trial finds adding the immunotherapy cancer drug durvalumab to radiation and chemotherapy significantly decreased the recurrence of lung cancer both in the chest area and in distant sites outside the chest. The updated PACIFIC trial data will be presented at the 61st Annual Meeting of the American Society for Radiation Oncology (ASTRO), by Andreas Rimner, MD, radiation oncologist, Memorial Sloan Kettering Cancer Center.

… Monday, September 16, 2019 Bottom Line: A new analysis of survival data for the randomized, phase III PACIFIC trial finds adding the immunotherapy cancer drug durvalumab to radiation and chemotherapy significantly decreased the recurrence of lung cancer both in the chest area and in distant sites outside

Sloan Kettering Institute scientists are using zebrafish to understand human skin cancer that attacks the hands and feet.

… Wednesday, March 30, 2022 To understand cancer in humans, researchers at the Sloan Kettering Institute (SKI) are turning to our distant relatives from 425 million years ago: fish. A lot has evolved since then: Fish use their fins to swim, whereas we use our hands to play Wordle. But there remains a deep